Answers are grounded in this paper and cite their sources.
Alzheimer’s disease prediction research seldom addresses bidirectional clinical-stage transitions, dynamic updating, and external calibration together. We evaluated the transportability of longitudinal predictions of improvement, persistence, and progression from Clinical Dementia Rating (CDR) 0.5. We conducted a retrospective prediction-model development and external-validation study using the Alzheimer’s Disease Neuroimaging Initiative (ADNI) for development, Open Access Series of Imaging Studies-3 (OASIS-3) for locked external validation, and the Australian Imaging, Biomarkers and Lifestyle study for descriptive feasibility assessment. Baseline and 90-day landmark models estimated first observed transitions to CDR 0 or CDR ≥ 1 and persistence at CDR 0.5 over 12 and 36 months. The dynamic model D1 incorporated updated Mini-Mental State Examination (MMSE) information into ridge-penalized cause-specific Cox models. Frozen external predictions were evaluated for discrimination, calibration, and prediction error; recalibration was assessed separately. ADNI included 2,447 index participants and 4,517 landmarks (1,412 participants); OASIS-3 included 491 index participants and 845 D1 landmarks (437 participants). Untouched D1 improvement/progression areas under the curve (AUCs) were 0.680/0.721 at 12 months and 0.747/0.729 at 36 months. Versus the static-information comparator (D0) on the same 845 OASIS-3 landmarks, D1 improved 12-month progression AUC by 0.071 (95% CI 0.024–0.129). At 36 months, improvement and progression AUC differences were 0.024 (0.001–0.051) and 0.029 (0.003–0.051), with a multistate Brier difference of − 0.014 (− 0.027 to − 0.002). D1 persistence discrimination was poor (AUC 0.502 at 12 months and 0.541 at 36 months). D1 improvement-risk observed-to-expected ratios were 2.154 at 12 months and 2.283 at 36 months, indicating substantial underprediction. Cross-fitted local recalibration reduced the 36-month multistate Brier score from 0.707 to 0.629. In ADNI, agreement between CDR improvement and sustained diagnosis reversion was limited (Jaccard 0.254; 0.456 under parallel sustained definitions). Limitations include clinical rather than biomarker-confirmed staging, research-cohort sampling, and incomplete death and dropout information. Updated cognition improved external prediction of selected CDR-stage transitions, but persistence discrimination was poor and absolute improvement risk did not transport adequately without updating. The results do not establish clinical deployment readiness. Observed CDR-stage improvement may be transient and must not be interpreted as biological recovery from Alzheimer’s disease.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: